Search - tctmd.com

Displaying 241 - 260 of 389

Sort: Relevancy | Date

Presentation TCT 2016

LIVE-IN-A-BOX CASE DEMONSTRATION: Mesentric Artery Intervention (Fibromuscular Dysplasia)

Presenter: Gary M. Ansel, Michael R. Jaff, D. Christopher Metzger

October 30, 2016

Presentation TCT 2016

Management of Visceral Artery Aneurysms: When to Intervene and How to Do It

Presenter: Gary M. Ansel, Michael R. Jaff, Constantino S. Pena

October 30, 2016

Presentation TCT 2016

Great Debate 1: The Optimal Management of Chronic Mesenteric Ischemia Is Catheter-based Intervention!

Presenter: Gary M. Ansel, Michael R. Jaff, Herbert D. Aronow

October 30, 2016

$TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia$

Presentation TCT 2016

TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia

Presenter: Tayo A. Addo, Jose de Ribamar Costa Jr, Francesco Giannini

October 30, 2016

Presentation TCT 2016

LIVE-IN-A-BOX CASE DEMONSTRATION: Renal Artery Intervention (Fibromuscular Dysplasia)

Presenter: Gary M. Ansel, Michael R. Jaff, D. Christopher Metzger

October 30, 2016

Presentation TCT 2016

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Presenter: Gary M. Ansel, Michael R. Jaff, Mehdi H. Shishehbor

October 30, 2016

Presentation TCT 2016

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Presenter: Gary M. Ansel, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

Atheroscleotic Renal Artery Intervention: What Are the Remaining Indications?

Presenter: Gary M. Ansel, Michael R. Jaff, Sahil A. Parikh

October 30, 2016

ILUMIEN 3: OCT Imaging Matches IVUS but Fails To Beat Angiography for Stent Guidance in PCI

News Conference News TCT 2016

ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI

Shelley Wood

October 30, 2016

News Conference News TCT 2015

Nordic-Baltic Bifurcation III: Kissing Balloon Dilatation Does Not Reduce MACE at 5 Years

October 16, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

Coronary CT Imaging: Ischemia vs Anatomy

Presenter: Hasan Jilaihawi, Christopher K. Zarins, James K. Min

October 14, 2015

Presentation TCT 2015

Case Introduction: A Complex Diabetic Patient With Heart Failure, Ischemia, and Mitral Regurgitation

Presenter: John D. Puskas

October 14, 2015

Presentation TCT 2015

Stable CAD With Substantial Ischemia and No-to-Mild Symptoms: Initial Revascularization vs Medical Therapy

Presenter: William A. Gray, Gregg W. Stone, D. Christopher Metzger, Sripal Bangalore

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

Advertisement

LIVE-IN-A-BOX CASE DEMONSTRATION: Mesentric Artery Intervention (Fibromuscular Dysplasia)

Management of Visceral Artery Aneurysms: When to Intervene and How to Do It

Great Debate 1: The Optimal Management of Chronic Mesenteric Ischemia Is Catheter-based Intervention!

TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia

LIVE-IN-A-BOX CASE DEMONSTRATION: Renal Artery Intervention (Fibromuscular Dysplasia)

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Atheroscleotic Renal Artery Intervention: What Are the Remaining Indications?

ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI

Nordic-Baltic Bifurcation III: Kissing Balloon Dilatation Does Not Reduce MACE at 5 Years

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Coronary CT Imaging: Ischemia vs Anatomy

Case Introduction: A Complex Diabetic Patient With Heart Failure, Ischemia, and Mitral Regurgitation

Stable CAD With Substantial Ischemia and No-to-Mild Symptoms: Initial Revascularization vs Medical Therapy

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content